تقرير تحليل حجم السوق العالمية لأدوية مضادات الهيستامين وحصة السوق واتجاهاتها - نظرة عامة على الصناعة وتوقعاتها حتى عام 2032

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL ANTIHISTAMINE DRUGS MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATION

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 KEY TAKEAWAYS

2.2 ARRIVING AT THE GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE

2.2.1 VENDOR POSITIONING GRID

2.2.2 TECHNOLOGY LIFE LINE CURVE

2.2.3 TRIPOD DATA VALIDATION MODEL

2.2.4 MARKET GUIDE

2.2.5 MULTIVARIATE MODELLING

2.2.6 TOP TO BOTTOM ANALYSIS

2.2.7 CHALLENGE MATRIX

2.2.8 APPLICATION COVERAGE GRID

2.2.9 STANDARDS OF MEASUREMENT

2.2.10 VENDOR SHARE ANALYSIS

2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS

2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES

2.3 GLOBAL ANTIHISTAMINE DRUGS MARKET: RESEARCH SNAPSHOT

2.4 ASSUMPTIONS

3 MARKET OVERVIEW

3.1 DRIVERS

3.2 RESTRAINTS

3.3 OPPORTUNITIES

3.4 CHALLENGES

4 EXECUTIVE SUMMARY

5 PREMIUM INSIGHTS

5.1 PESTEL ANALYSIS

5.2 PORTER’S FIVE FORCES MODEL

 

6 INDUSTRY INSIGHTS

6.1 MICRO AND MACRO ECONOMIC FACTORS

6.2 PENETRATION AND GROWTH PROSPECT MAPPING

6.3 KEY PRICING STRATEGIES

6.4 INTERVIEWS WITH SPECIALIST

6.5 ANALYIS AND RECOMMENDATION

7 INTELLECTUAL PROPERTY (IP) PORTFOLIO

7.1 PATENT QUALITY AND STRENGTH

7.2 PATENT FAMILIES

7.3 LICENSING AND COLLABORATIONS

7.4 COMPETITIVE LANDSCAPE

7.5 IP STRATEGY AND MANAGEMENT

7.6 OTHER

8 COST ANALYSIS BREAKDOWN

9 TECHNONLOGY ROADMAP

10 INNOVATION TRACKER AND STRATEGIC ANALYSIS

10.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS

10.1.1 JOINT VENTURES

10.1.2 MERGERS AND ACQUISITIONS

10.1.3 LICENSING AND PARTNERSHIP

10.1.4 TECHNOLOGY COLLABORATIONS

10.1.5 STRATEGIC DIVESTMENTS

10.2 NUMBER OF PRODUCTS IN DEVELOPMENT

10.3 STAGE OF DEVELOPMENT

10.4 TIMELINES AND MILESTONES

10.5 INNOVATION STRATEGIES AND METHODOLOGIES

10.6 RISK ASSESSMENT AND MITIGATION

10.7 MERGERS AND ACQUISITIONS

10.8 FUTURE OUTLOOK

11 EPIDEMIOLOGY

11.1 INCIDENCE OF ALL BY GENDER

11.2 TREATMENT RATE

11.3 MORTALITY RATE

11.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL

11.5 PATIENT TREATMENT SUCCESS RATES

12 REGULATORY COMPLIANCE

12.1 REGULATORY AUTHORITIES

12.2 REGULATORY CLASSIFICATIONS

12.2.1 CLASS I

12.2.2 CLASS II

12.2.3 CLASS III

12.3 REGULATORY SUBMISSIONS

12.4 INTERNATIONAL HARMONIZATION

12.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS

12.6 REGULATORY CHALLENGES AND STRATEGIES

13 PIPELINE ANALYSIS

13.1 CLINICAL TRIALS AND PHASE ANALYSIS

13.2 DRUG THERAPY PIPELINE

13.3 PHASE III CANDIDATES

13.4 PHASE II CANDIDATES

13.5 PHASE I CANDIDATES

13.6 OTHERS (PRE-CLINICAL AND RESEARCH)

TABLE 1 GLOBAL CLINICAL TRIAL MARKET FOR ANTIHISTAMINE DRUGS MARKET

Company Name Product Name

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

 

TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE FOR ANTIHISTAMINE DRUGS MARKET

Phase Number of Projects

Preclinical/Research Projects XX

Clinical Development XX

Phase I XX

Phase II XX

Phase III XX

U.S. Filed/Approved but Not Yet Marketed XX

Total XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE FOR ANTIHISTAMINE DRUGS MARKET

Therapeutic Area Preclinical/ Research Project

XX XX

XX XX

XX XX

XX XX

XX XX

Total Projects XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE FOR ANTIHISTAMINE DRUGS MARKET

Technology Preclinical/ Research Project

XX XX

XX XX

XX XX

XX XX

XX XX

Total Projects XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR ANTIHISTAMINE DRUGS MARKET

 

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

14 REIMBURSEMENT FRAMEWORK

15 OPPUTUNITY MAP ANALYSIS

16 VALUE CHAIN ANALYSIS

17 HEALTHCARE ECONOMY

17.1 HEALTHCARE EXPENDITURE

17.2 CAPITAL EXPENDITURE

17.3 CAPEX TRENDS

17.4 CAPEX ALLOCATION

17.5 FUNDING SOURCES

17.6 INDUSTRY BENCHMARKS

17.7 GDP RATION IN OVERALL GDP

17.8 HEALTHCARE SYSTEM STRUCTURE

17.9 GOVERNMENT POLICIES

17.1 ECONOMIC DEVELOPMENT

 

18 GLOBAL ANTIHISTAMINE DRUGS MARKET, BY THERAPY TYPE

(NOTE: MARKET VALUE, MARKET VOLUME AND ASP WILL BE PROVIDED FOR ALL SEGMENTS AND SUB-SEGMENTS)

18.1 OVERVIEW

18.2 MONOTHERAPY

18.3 COMBINATION THERAPY

19 GLOBAL ANTIHISTAMINE DRUGS MARKET, BY DRUG CLASS

(NOTE: MARKET VALUE, MARKET VOLUME AND ASP WILL BE PROVIDED FOR ALL SEGMENTS AND SUB-SEGMENTS)

19.1 OVERVIEW

19.2 FIRST GENERATION ANTIHISTAMINE (SEDATING)

19.2.1 BROMPHENIRAMINE

19.2.1.1. BY STREGHT

19.2.1.1.1. 1MG/1ML

19.2.1.1.2. 2 MG/5ML

19.2.1.1.3. OTHERS

19.2.1.2. BY DRUG TYPE

19.2.1.2.1. BRANDED

19.2.1.2.2. GENERICS

19.2.1.3. OTHERS

19.2.2 CARBINOXAMINE MALEATE

19.2.2.1. BY STREGHT

19.2.2.1.1. 4 MG

19.2.2.1.2. 10 MG

19.2.2.1.3. OTHERS

19.2.2.2. BY DRUG TYPE

19.2.2.2.1. BRANDED

19.2.2.2.2. GENERICS

19.2.2.3. OTHERS

19.2.3 CHLORPHENIRAMINE

19.2.3.1. BY STREGHT

19.2.3.1.1. 4 MG

19.2.3.1.2. 8 MG

19.2.3.1.3. 10 MG

19.2.3.1.4. OTHERS

 

19.2.3.2. BY DRUG TYPE

19.2.3.2.1. BRANDED

19.2.3.2.2. GENERICS

19.2.3.3. OTHERS

19.2.4 DIPHENHYDRAMINE

19.2.4.1. BY STREGHT

19.2.4.1.1. 25 MG

19.2.4.1.2. 50 MG

19.2.4.1.3. OTHERS

19.2.4.2. BY DRUG TYPE

19.2.4.2.1. BRANDED

19.2.4.2.2. GENERICS

19.2.4.3. OTHERS

19.2.5 HYDROXYZINE

19.2.5.1. BY STREGHT

19.2.5.1.1. 10 MG

19.2.5.1.2. 20 MG

19.2.5.1.3. 50 MG

19.2.5.1.4. OTHERS

19.2.5.2. BY DRUG TYPE

19.2.5.2.1. BRANDED

19.2.5.2.2. GENERICS

19.2.5.3. OTHERS

19.2.6 TRIPROLIDINE

19.2.6.1. BY STREGHT

19.2.6.1.1. 0.5MG/ML

19.2.6.1.2. 0.625MG/ML

19.2.6.1.3. OTHERS

19.2.6.2. BY DRUG TYPE

19.2.6.2.1. BRANDED

19.2.6.2.2. GENERICS

19.2.6.3. OTHERS

19.2.7 CLEMASTINE

19.2.7.1. BY STREGHT

19.2.7.1.1. 1.34MG

19.2.7.1.2. 2.68MG

19.2.7.1.3. OTHERS

19.2.7.2. BY DRUG TYPE

19.2.7.2.1. BRANDED

19.2.7.2.2. GENERICS

19.2.7.3. OTHERS

19.2.8 KETOTIFEN

19.2.8.1. BY STREGHT

19.2.8.1.1. 1MG

19.2.8.1.2. OTHERS

19.2.8.2. BY DRUG TYPE

19.2.8.2.1. BRANDED

19.2.8.2.2. GENERICS

19.2.8.3. OTHERS

19.2.9 PROMETHAZINE HYDROCHLORIDE

19.2.9.1. BY STREGHT

19.2.9.1.1. 12.5MG

19.2.9.1.2. 25MG

19.2.9.1.3. 50MG

19.2.9.1.4. OTHERS

19.2.9.2. BY DRUG TYPE

19.2.9.2.1. BRANDED

19.2.9.2.2. GENERICS

19.2.9.3. OTHERS

19.2.10 PROMETHAZINE TEOCLATE

19.2.10.1. BY STREGHT

19.2.10.1.1. 1.34MG

19.2.10.1.2. 2.68MG

19.2.10.1.3. OTHERS

19.2.10.2. BY DRUG TYPE

19.2.10.2.1. BRANDED

19.2.10.2.2. GENERICS

19.2.10.3. OTHERS

19.2.11 CYPROHEPTADINE

19.2.11.1. BY STREGHT

19.2.11.1.1. 4 MG

19.2.11.1.2. OTHERS

19.2.11.2. BY DRUG TYPE

19.2.11.2.1. BRANDED

19.2.11.2.2. GENERICS

19.2.11.3. OTHERS

19.2.12 CINNARIZINE

19.2.12.1. BY STREGHT

19.2.12.1.1. 15 MG

19.2.12.1.2. 25 MG

19.2.12.1.3. OTHERS

19.2.12.2. BY DRUG TYPE

19.2.12.2.1. BRANDED

19.2.12.2.2. GENERICS

19.2.12.3. OTHERS

19.2.13 ALIMEMAZINE

19.2.13.1. BY STREGHT

19.2.13.1.1. 1 MG

19.2.13.1.2. 10 MG

19.2.13.1.3. OTHERS

19.2.13.2. BY DRUG TYPE

19.2.13.2.1. BRANDED

19.2.13.2.2. GENERICS

19.2.13.3. OTHERS

19.2.14 OTHERS

19.3 SECOND GENERATION ANTIHISTAMINES (NON SEDATING)

19.3.1 AZELASTINE

19.3.1.1. BY STREGHT

19.3.1.1.1. 0.1% SOLUTION

19.3.1.1.2. 0.15% SOLUTION

19.3.1.2. BY DRUG TYPE

19.3.1.2.1. BRANDED

19.3.1.2.2. GENERICS

19.3.1.3. OTHERS

19.3.2 OLOPATADINE

19.3.2.1. BY STREGHT

19.3.2.1.1. 0.1% SOLUTION

19.3.2.1.2. 0.2% SOLUTION

19.3.2.2. BY DRUG TYPE

19.3.2.2.1. BRANDED

19.3.2.2.2. GENERICS

19.3.2.3. OTHERS

19.3.3 ACRIVASTINE

19.3.3.1. BY STREGHT

19.3.3.1.1. 8 MG

19.3.3.1.2. 60 MG

19.3.3.2. BY DRUG TYPE

19.3.3.2.1. BRANDED

19.3.3.2.2. GENERICS

19.3.3.3. OTHERS

19.3.4 BILASTINE

19.3.4.1. BY STREGHT

19.3.4.1.1. 10 MG

19.3.4.1.2. 20 MG

19.3.4.1.3. OTHERS

19.3.4.2. BY DRUG TYPE

19.3.4.2.1. BRANDED

19.3.4.2.2. GENERICS

19.3.4.3. OTHERS

19.3.5 DESLORATADINE

19.3.5.1. BY STREGHT

19.3.5.1.1. 2.5 MG

19.3.5.1.2. 5 MG

19.3.5.1.3. OTHERS

19.3.5.2. BY DRUG TYPE

19.3.5.2.1. BRANDED

19.3.5.2.2. GENERICS

19.3.5.3. OTHERS

19.3.6 FEXOFENADINE

19.3.6.1. BY STREGHT

19.3.6.1.1. 30 MG

19.3.6.1.2. 60 MG

19.3.6.1.3. 180 MG

19.3.6.1.4. OTHERS

19.3.6.2. BY DRUG TYPE

19.3.6.2.1. BRANDED

19.3.6.2.2. GENERICS

19.3.6.3. OTHERS

19.3.7 CETIRIZINE

19.3.7.1. BY STREGHT

19.3.7.1.1. 5 MG

19.3.7.1.2. 10 MG

19.3.7.1.3. OTHERS

19.3.7.2. BY DRUG TYPE

19.3.7.2.1. BRANDED

19.3.7.2.2. GENERICS

19.3.7.3. OTHERS

 

19.3.8 LEVOCETIRIZINE

19.3.8.1. BY STREGHT

19.3.8.1.1. 5 MG

19.3.8.1.2. 2.5 MG

19.3.8.1.3. OTHERS

19.3.8.2. BY DRUG TYPE

19.3.8.2.1. BRANDED

19.3.8.2.2. GENERICS

19.3.8.3. OTHERS

19.3.9 LORATADINE

19.3.9.1. BY STREGHT

19.3.9.1.1. 5 MG

19.3.9.1.2. 10 MG

19.3.9.1.3. OTHERS

19.3.9.2. BY DRUG TYPE

19.3.9.2.1. BRANDED

19.3.9.2.2. GENERICS

19.3.9.3. OTHERS

19.3.10 MIZOLASTINE

19.3.10.1. BY STREGHT

19.3.10.1.1. 10 MG

19.3.10.1.2. OTHERS

19.3.10.2. BY DRUG TYPE

19.3.10.2.1. BRANDED

19.3.10.2.2. GENERICS

19.3.10.3. OTHERS

19.3.11 RUPATADINE

19.3.11.1. BY STREGHT

19.3.11.1.1. 10 MG

19.3.11.1.2. OTHERS

19.3.11.2. BY DRUG TYPE

19.3.11.2.1. BRANDED

19.3.11.2.2. GENERICS

19.3.11.3. OTHERS

19.3.12 OTHERS

19.4 OTHER

 

20 GLOBAL ANTIHISTAMINE DRUGS MARKET, BY ROUTE OF ADMINISTRATION

20.1 OVERVIEW

20.2 ORAL

20.2.1 CAPSULES

20.2.2 TABLETS

20.2.3 OTHERS

20.3 PARENTERAL

20.3.1 INTRAVENEOUS

20.3.2 SUBCUTANEOUS

20.3.3 OTHERS

20.4 INTRANASAL

20.5 INTRAOCULAR

20.6 OTHERS

21 GLOBAL ANTIHISTAMINE DRUGS MARKET, BY DRUG TYPE

21.1 OVERVIEW

21.2 BRANDED

21.2.1 ZYRTEC D

21.2.2 XYZAL

21.2.3 CLARINEX

21.2.4 OTHERS

21.3 GENERICS

22 GLOBAL ANTIHISTAMINE DRUGS MARKET, BY PRESCRIPTION MODE

22.1 OVERVIEW

22.2 PRESCRIPTION-BASED

22.2.1 ASTELIN

22.2.2 ARBINOXA

22.2.3 OTHERS

22.3 OVER-THE-COUNTER (OTC)

23 GLOBAL ANTIHISTAMINE DRUGS MARKET, BY POPULATION TYPE

23.1 OVERVIEW

23.2 BELOW 6 YEARS

23.3 6-15 YEARS

23.4 ABOVE 15 YEARS

 

24 GLOBAL ANTIHISTAMINE DRUGS MARKET, BY GENDER

24.1 OVERVIEW

24.2 MALE

24.2.1 BELOW 6 YEARS

24.2.2 6-15 YEARS

24.2.3 ABOVE 15 YEARS

24.3 FEMALE

24.3.1 BELOW 6 YEARS

24.3.2 6-15 YEARS

24.3.3 ABOVE 15 YEARS

25 GLOBAL ANTIHISTAMINE DRUGS MARKET, BY INDICATION

25.1 OVERVIEW

25.2 URTICARIA

25.3 ALLERGY

25.3.1 ALLERGIC RHINITIS

25.3.2 ALLERGIC CONJUNCTIVITIS

25.3.3 ALLERGIC DERMATOLOGICAL REACTION

25.3.4 OTHERS

25.4 DERMATITIS

25.5 SINUSITIS

25.6 PEPTIC ULCER

25.7 ZOLLINGER ELLISON SYNDROME

25.8 OTHER

26 GLOBAL ANTIHISTAMINE DRUGS MARKET, BY END USER

26.1 OVERVIEW

26.2 HOSPITALS

26.2.1 PUBLIC

26.2.2 PRIVATE

26.3 SPECIALTY CLINICS

26.4 HOME HEALTHCARE

26.5 ACADEMIC AND RESEARCH INSTITUTE

26.6 OTHERS

 

27 GLOBAL ANTIHISTAMINE DRUGS MARKET, BY DISTRIBUTION CHANNEL

27.1 OVERVIEW

27.2 DIRECT TENDER

27.3 RETAIL SALES

27.3.1 ONLINE PHARMACY

27.3.2 OFFLINE PHARMACY

27.4 OTHERS

28 GLOBAL ANTIHISTAMINE DRUGS MARKET, COMPANY LANDSCAPE

28.1 COMPANY SHARE ANALYSIS: GLOBAL

28.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

28.3 COMPANY SHARE ANALYSIS: EUROPE

28.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

28.5 MERGERS & ACQUISITIONS

28.6 NEW PRODUCT DEVELOPMENT & APPROVALS

28.7 EXPANSIONS

28.8 REGULATORY CHANGES

28.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

29 GLOBAL ANTIHISTAMINE DRUGS MARKET, BY REGION

GLOBAL ANTIHISTAMINE DRUGS MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)

29.1 NORTH AMERICA

29.1.1 U.S.

29.1.2 CANADA

29.1.3 MEXICO

29.2 EUROPE

29.2.1 GERMANY

29.2.2 U.K.

29.2.3 ITALY

29.2.4 FRANCE

29.2.5 SPAIN

29.2.6 RUSSIA

29.2.7 SWITZERLAND

29.2.8 TURKEY

29.2.9 BELGIUM

29.2.10 NETHERLANDS

29.2.11 DENMARK

29.2.12 SWEDEN

29.2.13 POLAND

29.2.14 NORWAY

29.2.15 FINLAND

29.2.16 REST OF EUROPE

29.3 ASIA-PACIFIC

29.3.1 JAPAN

29.3.2 CHINA

29.3.3 SOUTH KOREA

29.3.4 INDIA

29.3.5 SINGAPORE

29.3.6 THAILAND

29.3.7 INDONESIA

29.3.8 MALAYSIA

29.3.9 PHILIPPINES

29.3.10 AUSTRALIA

29.3.11 NEW ZEALAND

29.3.12 VIETNAM

29.3.13 TAIWAN

29.3.14 REST OF ASIA-PACIFIC

29.4 SOUTH AMERICA

29.4.1 BRAZIL

29.4.2 ARGENTINA

29.4.3 REST OF SOUTH AMERICA

29.5 MIDDLE EAST AND AFRICA

29.5.1 SOUTH AFRICA

29.5.2 EGYPT

29.5.3 BAHRAIN

29.5.4 UNITED ARAB EMIRATES

29.5.5 KUWAIT

29.5.6 OMAN

29.5.7 QATAR

29.5.8 SAUDI ARABIA

29.5.9 REST OF MEA

29.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES

30 GLOBAL ANTIHISTAMINE DRUGS MARKET, SWOT AND DBMR ANALYSIS

 

31 GLOBAL ANTIHISTAMINE DRUGS MARKET, COMPANY PROFILE

31.1 VITARIS INC.

31.1.1 COMPANY OVERVIEW

31.1.2 REVENUE ANALYSIS

31.1.3 GEOGRAPHIC PRESENCE

31.1.4 PRODUCT PORTFOLIO

31.1.5 RECENT DEVELOPMENTS

31.2 JOHNSON & JOHNSON SERVICES, INC.

31.2.1 COMPANY OVERVIEW

31.2.2 REVENUE ANALYSIS

31.2.3 GEOGRAPHIC PRESENCE

31.2.4 PRODUCT PORTFOLIO

31.2.5 RECENT DEVELOPMENTS

31.3 ACTAVIS ELIZABETH LLC

31.3.1 COMPANY OVERVIEW

31.3.2 REVENUE ANALYSIS

31.3.3 GEOGRAPHIC PRESENCE

31.3.4 PRODUCT PORTFOLIO

31.3.5 RECENT DEVELOPMENTS

31.4 APOTEX INC.

31.4.1 COMPANY OVERVIEW

31.4.2 REVENUE ANALYSIS

31.4.3 GEOGRAPHIC PRESENCE

31.4.4 PRODUCT PORTFOLIO

31.4.5 RECENT DEVELOPMENTS

31.5 CARACO PHARMACEUTICAL LABORATORIES, LTD (SUN PHARMACEUTICAL INDUSTRIES LTD)

31.5.1 COMPANY OVERVIEW

31.5.2 REVENUE ANALYSIS

31.5.3 GEOGRAPHIC PRESENCE

31.5.4 PRODUCT PORTFOLIO

31.5.5 RECENT DEVELOPMENTS

31.6 DR. REDDY’S LABORATORIES LTD.

31.6.1 COMPANY OVERVIEW

31.6.2 REVENUE ANALYSIS

31.6.3 GEOGRAPHIC PRESENCE

31.6.4 PRODUCT PORTFOLIO

31.6.5 RECENT DEVELOPMENTS

 

31.7 PERRIGO COMPANY PLC

31.7.1 COMPANY OVERVIEW

31.7.2 REVENUE ANALYSIS

31.7.3 GEOGRAPHIC PRESENCE

31.7.4 PRODUCT PORTFOLIO

31.7.5 RECENT DEVELOPMENTS

31.8 SANDOZ AG (NOVARTIS AG)

31.8.1 COMPANY OVERVIEW

31.8.2 REVENUE ANALYSIS

31.8.3 GEOGRAPHIC PRESENCE

31.8.4 PRODUCT PORTFOLIO

31.8.5 RECENT DEVELOPMENTS

31.9 WOCKHARDT USA

31.9.1 COMPANY OVERVIEW

31.9.2 REVENUE ANALYSIS

31.9.3 GEOGRAPHIC PRESENCE

31.9.4 PRODUCT PORTFOLIO

31.9.5 RECENT DEVELOPMENTS

31.1 PFIZER INC.

31.10.1 COMPANY OVERVIEW

31.10.2 REVENUE ANALYSIS

31.10.3 GEOGRAPHIC PRESENCE

31.10.4 PRODUCT PORTFOLIO

31.10.5 RECENT DEVELOPMENTS

31.11 TRINITY PHARMA (PTY) LTD.

31.11.1 COMPANY OVERVIEW

31.11.2 REVENUE ANALYSIS

31.11.3 GEOGRAPHIC PRESENCE

31.11.4 PRODUCT PORTFOLIO

31.11.5 RECENT DEVELOPMENTS

31.12 AVET PHARMACEUTICALS INC

31.12.1 COMPANY OVERVIEW

31.12.2 REVENUE ANALYSIS

31.12.3 GEOGRAPHIC PRESENCE

31.12.4 PRODUCT PORTFOLIO

31.12.5 RECENT DEVELOPMENTS

 

31.13 TEVA PHARMACEUTICALS USA, INC.

31.13.1 COMPANY OVERVIEW

31.13.2 REVENUE ANALYSIS

31.13.3 GEOGRAPHIC PRESENCE

31.13.4 PRODUCT PORTFOLIO

31.13.5 RECENT DEVELOPMENTS

31.14 CIPLA

31.14.1 COMPANY OVERVIEW

31.14.2 REVENUE ANALYSIS

31.14.3 GEOGRAPHIC PRESENCE

31.14.4 PRODUCT PORTFOLIO

31.14.5 RECENT DEVELOPMENTS

31.15 TAJ PHARMA GROUP

31.15.1 COMPANY OVERVIEW

31.15.2 REVENUE ANALYSIS

31.15.3 GEOGRAPHIC PRESENCE

31.15.4 PRODUCT PORTFOLIO

31.15.5 RECENT DEVELOPMENTS

31.16 UCB S.A.

31.16.1 COMPANY OVERVIEW

31.16.2 REVENUE ANALYSIS

31.16.3 GEOGRAPHIC PRESENCE

31.16.4 PRODUCT PORTFOLIO

31.17 CAMBER PHARMACEUTICALS, INC

31.17.1 COMPANY OVERVIEW

31.17.2 REVENUE ANALYSIS

31.17.3 GEOGRAPHIC PRESENCE

31.17.4 PRODUCT PORTFOLIO

31.18 GLENMARK PHARMACEUTICALS INC., USA

31.18.1 COMPANY OVERVIEW

31.18.2 REVENUE ANALYSIS

31.18.3 GEOGRAPHIC PRESENCE

31.18.4 PRODUCT PORTFOLIO

31.19 WELLONA PHARMA

31.19.1 COMPANY OVERVIEW

31.19.2 REVENUE ANALYSIS

31.19.3 GEOGRAPHIC PRESENCE

31.19.4 PRODUCT PORTFOLIO

 

31.2 ADVACARE PHARMA

31.20.1 COMPANY OVERVIEW

31.20.2 REVENUE ANALYSIS

31.20.3 GEOGRAPHIC PRESENCE

31.20.4 PRODUCT PORTFOLIO

31.21 ERIS LIFESCIENCES

31.21.1 COMPANY OVERVIEW

31.21.2 REVENUE ANALYSIS

31.21.3 GEOGRAPHIC PRESENCE

31.21.4 PRODUCT PORTFOLIO

31.21.5 RECENT DEVELOPMENTS

31.22 SANOFI

31.22.1 COMPANY OVERVIEW

31.22.2 REVENUE ANALYSIS

31.22.3 GEOGRAPHIC PRESENCE

31.22.4 PRODUCT PORTFOLIO

31.22.5 RECENT DEVELOPMENTS

31.23 ADEN HEALTHCARE

31.23.1 COMPANY OVERVIEW

31.23.2 REVENUE ANALYSIS

31.23.3 GEOGRAPHIC PRESENCE

31.23.4 PRODUCT PORTFOLIO

31.23.5 RECENT DEVELOPMENTS

31.24 ORGANON GROUP OF COMPANIES

31.24.1 COMPANY OVERVIEW

31.24.2 REVENUE ANALYSIS

31.24.3 GEOGRAPHIC PRESENCE

31.24.4 PRODUCT PORTFOLIO

31.24.5 RECENT DEVELOPMENTS

31.25 MERCK & CO., INC

31.25.1 COMPANY OVERVIEW

31.25.2 REVENUE ANALYSIS

31.25.3 GEOGRAPHIC PRESENCE

31.25.4 PRODUCT PORTFOLIO

31.25.5 RECENT DEVELOPMENTS

 

31.26 LUPIN PHARMACEUTICALS, INC.

31.26.1 COMPANY OVERVIEW

31.26.2 REVENUE ANALYSIS

31.26.3 GEOGRAPHIC PRESENCE

31.26.4 PRODUCT PORTFOLIO

31.26.5 RECENT DEVELOPMENTS

31.27 ORBION PHARMACEUTICALS PRIVATE LTD

31.27.1 COMPANY OVERVIEW

31.27.2 REVENUE ANALYSIS

31.27.3 GEOGRAPHIC PRESENCE

31.27.4 PRODUCT PORTFOLIO

31.27.5 RECENT DEVELOPMENTS

31.28 SCIEGEN PHARMACEUTICALS INC

31.28.1 COMPANY OVERVIEW

31.28.2 REVENUE ANALYSIS

31.28.3 GEOGRAPHIC PRESENCE

31.28.4 PRODUCT PORTFOLIO

31.28.5 RECENT DEVELOPMENTS

31.29 STRIDES PHARMA GLOBAL PTE LTD

31.29.1 COMPANY OVERVIEW

31.29.2 REVENUE ANALYSIS

31.29.3 GEOGRAPHIC PRESENCE

31.29.4 PRODUCT PORTFOLIO

31.29.5 RECENT DEVELOPMENTS

31.3 SYNTHON B.V.

31.30.1 COMPANY OVERVIEW

31.30.2 REVENUE ANALYSIS

31.30.3 GEOGRAPHIC PRESENCE

31.30.4 PRODUCT PORTFOLIO

31.30.5 RECENT DEVELOPMENTS

32 REPORTS

33 CONCLUSION

34 QUESTIONNAIRE

35 ABOUT DATA BRIDGE MARKET RESEARCH